Overview
Cleidocranial dysplasia (CCD), also known as cleidocranial dysostosis or Marie-Sainton disease, is a rare skeletal disorder characterized by defective development of bones, particularly those formed through membranous ossification. It is caused by mutations in the RUNX2 gene (also called CBFA1), located on chromosome 6p21, which encodes a transcription factor essential for osteoblast differentiation and bone formation. The condition affects multiple body systems, most notably the skeletal system and dentition. The hallmark features of cleidocranial dysplasia include hypoplastic or absent clavicles (collarbones), which allow affected individuals to approximate their shoulders anteriorly in a characteristic fashion. Skull abnormalities are prominent and include delayed closure of cranial sutures and fontanelles, which may remain open throughout life, as well as frontal and parietal bossing, giving the head a broad appearance. Dental abnormalities are a major clinical concern and include delayed eruption or failure of eruption of permanent teeth, supernumerary (extra) teeth, and retention of primary (deciduous) teeth. Other skeletal features may include short stature, a wide pubic symphysis, brachydactyly, scoliosis, and other vertebral anomalies. Hearing loss may also occur due to structural abnormalities of the ossicles or external ear canal. There is currently no cure for cleidocranial dysplasia, and management is multidisciplinary. Dental care is often the most significant aspect of treatment, frequently requiring surgical-orthodontic interventions to remove supernumerary teeth and facilitate eruption of permanent teeth. Orthopedic monitoring is important for skeletal complications. Hearing assessments should be performed regularly. Protective headgear may be recommended in young children with widely open fontanelles. Genetic counseling is advised for affected families, as approximately one-third of cases arise from de novo mutations with no prior family history.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventJohns Hopkins University
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Cleidocranial dysplasia.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Cleidocranial dysplasia.
Community
No community posts yet. Be the first to share your experience with Cleidocranial dysplasia.
Start the conversation →Latest news about Cleidocranial dysplasia
No recent news articles for Cleidocranial dysplasia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cleidocranial dysplasia
What is Cleidocranial dysplasia?
Cleidocranial dysplasia (CCD), also known as cleidocranial dysostosis or Marie-Sainton disease, is a rare skeletal disorder characterized by defective development of bones, particularly those formed through membranous ossification. It is caused by mutations in the RUNX2 gene (also called CBFA1), located on chromosome 6p21, which encodes a transcription factor essential for osteoblast differentiation and bone formation. The condition affects multiple body systems, most notably the skeletal system and dentition. The hallmark features of cleidocranial dysplasia include hypoplastic or absent clav
How is Cleidocranial dysplasia inherited?
Cleidocranial dysplasia follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Cleidocranial dysplasia typically begin?
Typical onset of Cleidocranial dysplasia is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Cleidocranial dysplasia?
Yes — 1 recruiting clinical trial is currently listed for Cleidocranial dysplasia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Cleidocranial dysplasia?
1 specialists and care centers treating Cleidocranial dysplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.